Epic as an Effective, Low Toxicity Salvage Therapy for Patients with Poor Risk Lymphoma Prior to Beam High Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation-Reference-Cited by-同舟云学术

Epic as an Effective, Low Toxicity Salvage Therapy for Patients with Poor Risk Lymphoma Prior to Beam High Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation

Published:1999-01 Issue:3-4 Volume:35 Page:339-345
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

McBride N. C.,Ward M. C.,Mills M. J.,Eden A. G.,Hughes A.,Cavenagh J. D.,Lamont A.,Newland A. C.,Kelsey S. M.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199909145738

Reference19 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

2. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patients

3. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

4. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease

5. The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi;Infectious Agents and Cancer;2017-08-09

2. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim;Internal Medicine Journal;2007-06-02

3. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens;British Journal of Haematology;2005-08

4. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival;Bone Marrow Transplantation;2001-02

5. Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma;Leukemia & Lymphoma;2001-01